卵巢刺激期间使用芳香化酶抑制剂可抑制异种移植小鼠模型中子宫内膜癌的生长
研究将40只移植人子宫内膜癌细胞(Ishikawa 3-H-12,雌激素与孕激素受体阳性)的裸鼠分为4组,在6周治疗期内观察肿瘤生长。与单纯卵巢刺激组相比,卵巢刺激联合芳香化酶抑制剂组、无卵巢刺激对照组及卵巢切除加卵巢刺激组的肿瘤生长均受到显著抑制(均P < 0.05),且与雌激素水平相关;芳香化酶抑制剂对胚胎发育无明显影响。
要点
- 在异种移植小鼠模型中,卵巢刺激联合芳香化酶抑制剂可显著抑制子宫内膜癌生长(P < 0.05)。
- 肿瘤生长抑制与雌激素水平相关,芳香化酶抑制剂对胚胎发育无明显影响。
- 作者认为,对子宫内膜癌或增生患者,同期使用芳香化酶抑制剂可能为其提供更安全分娩的机会。
核心结论
- 在子宫内膜癌异种移植小鼠模型中,卵巢刺激期间同期给予芳香化酶抑制剂可抑制子宫内膜癌的生长。
- 作者认为,同期使用芳香化酶抑制剂可能为子宫内膜癌或增生患者提供更安全分娩的机会。
研究设计与样本
- 研究为异种移植小鼠模型研究,40只移植子宫子宫内膜癌细胞的裸鼠被分配至4组。
- 第1组为无卵巢刺激(对照),第2组为卵巢刺激,第3组为芳香化酶抑制剂加卵巢刺激,第4组为卵巢切除加卵巢刺激。
- 将Ishikawa 3-H-12子宫子宫内膜癌细胞(雌激素与孕激素受体阳性)移植入6周龄BALB/cSlc-nu/nu裸鼠,2周后实施干预。
- 在6周治疗期内评估肿瘤生长。
主要发现
- 与单纯卵巢刺激组(第2组)相比,其余三组(第1、3、4组)均观察到肿瘤生长显著受抑制,均P < 0.05。
- 肿瘤生长抑制与雌激素水平相关。
- 芳香化酶抑制剂给药对胚胎发育无明显影响。
临床怎么用
- 作者认为,同期使用芳香化酶抑制剂可能为子宫内膜癌或增生患者提供更安全分娩的机会。
局限性
- 本研究仅使用一种子宫内膜癌细胞系来 examine 子宫内膜癌肿瘤的生长。
- 临床子宫内膜癌或增生细胞来源多样,芳香化酶抑制剂可能对其他癌细胞类型无效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Could aromatase inhibitors (AI) be used to reduce risks of uterine endometrial cancer growth or recurrence during ovarian stimulation? SUMMARY ANSWER: In a xenograft mouse model of endometrial cancer, concomitant AI administration suppressed the growth of endometrial cancer during ovarian stimulation. WHAT IS KNOWN ALREADY: Recurrence and mortality rates of estrogen receptor-positive early breast cancer are reduced by long-term AI administration. Concomitant AI use for ovarian stimulation in patients with breast cancer is recommended for reducing estrogen-related potential risks. However, the efficacy of concomitant AI use for estrogen receptor-positive endometrial cancer have not been demonstrated conclusively by clinical or experimental animal studies. STUDY DESIGN, SIZE, DURATION: Forty nude mice xenografted with uterine endometrial cancer cells were allocated to four groups. Group 1: no ovarian stimulation (control). Group 2: ovarian stimulation. Group 3: AI administration + ovarian stimulation. Group 4: ovariectomy and ovarian stimulation. Tumor growth was evaluated during the 6-week treatment period. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ishikawa 3-H-12 uterine endometrial cancer cells (estrogen and progesterone receptors-positive) were transplanted into 6-week-old BALB/cSlc-nu/nu nude mice, followed by interventions 2 weeks later. MAIN RESULTS AND THE ROLE OF CHANCE: Compared to ovarian stimulation alone (Group 2), significant suppressions of tumor growth were observed in other three groups (Groups 1, 3 and 4, all at P < 0.05) and correlated with estrogen levels. AI administration had no apparent impact on embryo development. LIMITATIONS, REASONS FOR CAUTION: In this study, we examined the growth of endometrial cancer tumors using one endometrial cancer cell line. Clinical endometrial cancer or hyperplasia cells can have diverse origins and AI may not be effective against other cancer cell types. WIDER IMPLICATIONS OF THE FINDINGS: Concomitant AI use may provide a chance for safer childbirth by for patients with endometrial cancer or hyperplasia. STUDY FUNDING/CONPETING INTEREST(S): This study was supported by the Graduate Student Aid from the St. Marianna University School of Medicine. The authors declare no competing interests.
引用
- Kawahara T, Okamoto N, Takae S, et al. Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model. Hum Reprod. 2018. PMID: 29300901. doi:10.1093/humrep/dex368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。